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Identity 
Hugo: GRB2 
Other names: ASH (Abundant Src Homology); Grb3-
3; MST084; MSTP084; HTO27; EGFRBP (Epidermal 
Growth Factor Receptor Binding Protein)-GRB2 
Location: 17q25.1 
Local order: Chromosome 17, 87,632 bases, 5'- 
70913384 - 70825752 -3'; strand: (-). The human 
GRB2 gene is telomeric to GGA3 (Golgi associated, 
gamma adaptin ear containing, ARF binding protein 3) 
and centromeric to ITGB4 (integrin, beta 4). 
DNA/RNA 
Transcription 
The GRB2 gene structure consists of five exons 
(ranging from 78 to 186 bp) and four introns (from 
approximately 1 to approximately 7 kb). Two human 
mRNA transcript variants arise from alternative 
splicing. GRB2 variant 1 mRNA encodes protein 
isoform 1, which is longer. Variant 2 mRNA, which 
encodes protein isoform 2, lacks an in-frame exon 
present in the 3' coding region of variant 1 
encompassing residues 59-100 of the mature protein 
(see Protein, below). 
Pseudogene 
At least one potential human pseudogene may exist: 
LOC391157. A pseudogene of the mouse Grb2 
homolog, known as Grb2-ps1 (growth factor receptor 
bound protein 2, pseudogene 1) also has been 
identified. 
 
 
 
Protein 
 
 
A schematic representation of the domain structure of GRB2, 
which consists of a single Src homology 2 (SH2) domain 
(residues 59-152) flanked by two SH3 domains (amino-
terminal: residues 3-54; carboxy-terminal: residues 160-212). 
Description 
GRB2 (isoform 1) is a 217 residue protein with an 
expected molecular mass of 25,206 Da. GRB2 protein 
has homology to non-catalytic regions of c-Src, 
consisting of a single Src homology 2 (SH2) domain 
flanked by two Src homology 3 (SH3) domains. GRB2 
isoform 2, encoded by an alternatively spliced mRNA 
transcript known as variant 2, has a deletion in the 
amino-terminal portion of the SH2 domain 
encompassing residues 59-100 of isoform 1. This 
protein isoform, known originally as GRB3-3, does not 
bind to phosphotyrosyl-containing proteins like isoform 
1, but retains two functional SH3 domains. 
Expression 
Expressed in virtually all embryonic and adult tissues. 
Localisation 
Primarily cytosolic, but transient plasma membrane and 
nuclear localizations have been reported. 
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Function 
Cell surface receptor signalling: The two GRB2 SH3 
domains bind to the proline-rich regions of the guanine 
nucleotide releasing factor son of sevenless (SOS-1) 
protein, and the GRB2-SOS-1 complex preexists in the 
cytoplasm of resting cells. Phosphotyrosyl residues on 
in the context of the motif NH2- pYXNX-COOH 
(where pY represents phosphotyrosine, N represents 
asparagine, and X represents any other residue) are 
selectively recognized by the GRB2 SH2 domain. 
Growth factor receptor tyrosine kinases (RTKs), 
including those for epidermal growth factor (EGF), 
fibroblast growth factor, nerve growth factor 
(TrkA/TrkB), platelet-derived growth factor, colony-
stimulating factor-1, and hepatocyte growth factor 
(HGF), as well as non-receptor tyrosine kinases (TKs) 
such as BCR - Abl and focal adhesion kinase (FAK), 
intracellular effectors such as insulin receptor substrate-
1 and Shc, and phosphotyrosine phosphatases such as 
SHP-2 (PTPN11) and receptor-like tyrosine 
phosphatase alpha, all conditionally possess the 
pYXNX motif. Note that the environmental cue leading 
to protein tyrosyl phosphorylation on an appropriate 
GRB2 recognition motif is independent of GRB2 
interaction; thus, ligand independent EGFR activation, 
such as growth hormone-induced EGFR tyrosine 
phosphorylation by JAK2, also leads to GRB2-
mediated ERK kinase pathway activation and c-fos 
expression. Similarly, mechanical stress leading to 
increased angiotensin II production and transactivation 
of EGFR and other intracellular kinases implicates 
GRB2 recruitment in cardiac hypertrophy and 
myocardial remodeling. 
In many mitogenic signaling pathways, recruitment of 
GRB2 from the cytosol, where it is already bound to 
the guanine nucleotide exchange factor SOS-1 via its 
amino-terminal SH3 domain, brings SOS1 in close 
proximity to Ras at the plasma membrane. Ras, a small 
GTPase in the GDP-bound inactive state in quiescent 
cells, then undergoes nucleotide exchange of GDP for 
GTP, which facilitates binding of the serine/threonine 
protein kinase Raf-1 and its subsequent activation. This 
initiates a cascade of kinase activation: activated Raf-1 
phosphorylates and activates MEK1/MEK2, which in 
turn phosphorylate and stimulate the MAP kinases 
ERK1/ERK2. Activated ERKs translocate to the 
nucleus and phosphorylate transcription factors such as 
Elk-1, STAT1, STAT3 and Myc, activating gene 
expression. In parallel, the phosphatidyl inositol 3-
kinase (PI3K)/Akt pathway is activated via the adaptor 
Gab1, which is bound to the GRB2 carboxyl-terminal 
SH3 domain in many epithelial cell types. The gene 
expression programs activated by these pathways 
initiate a spectrum of fundamental cellular activities 
including proliferation, growth (increase in cell size), 
differentiation and survival. These processes are critical  
for normal embryonic development and adult 
homeostasis, and are frequently aberrantly activated in 
cancer. 
Stimulation of the T cell antigen receptor (TCR) 
induces the tyrosine phosphorylation of a variety of 
cellular proteins, including a protein called p36-38 or 
Linker for Activation of T cells (LAT), a protein tightly 
associated with the plasma membrane. Tyrosyl-
phosphorylated sequences of LAT bind to the GRB2 
SH2 domain. In these cells the SH3 domains of GRB2 
bind Vav-family proteins, guanine nucleotide exchange 
factors for Rho-family GTPases. These interactions are 
essential for TCR-induced calcium flux and activation 
of the MAP kinase cascade, ultimately leading to T cell 
proliferation and effector functions. 
Receptor endocytosis and ubiquitinylation: Upon 
ligand-dependant activation of EGFR TK, c-Cbl binds 
to the EGFR directly through its SH2 domain and 
indirectly through its SH3 domain. c-Cbl binding and 
its consequential phosphorylation results in activation 
of the E3 ubiquitin ligase complex of which c-Cbl is a 
component, resulting in receptor ubiquitinylation. 
GRB2 also regulates internalization of EGF receptors 
through clathrin-coated pits. 
Actin-based cell motility: GRB2 participates directly 
in the regulation of actin filament formation and actin-
based cell motility. GRB2 is a critical link between 
Wiskott-Aldrich Syndrome protein (WASp) and the 
actin cytoskeleton; WAS patients show defects in T cell 
polarization and migration in response to physiologic 
stimuli, resulting in thrombocytopenia, eczema and 
immunodeficiency. Studies of WASp function and the 
intracellular motility of invasive microbial pathogens 
such as Listeria monocytogenes and Vaccinia virus 
helped to elucidate an important role for GRB2 in 
directly promoting actin based motility. In most 
mammalian cells, the WASp family member N-WASp 
interacts with the Arp2/3 complex and G-actin to 
stimulate actin polymerization. N-WASp activity is 
enhanced by other effectors such as Nck, Cdc42 and 
GRB2; disruption of GRB2 SH3 or SH2 domains 
diminishes actin polymerization and thus actin-based 
motility. 
Homology 
GRB2 amino acid sequence is very highly conserved 
among species. Human GRB2 shows 50% overall 
amino acid sequence identity with S. cerevisiae 
YPR154w, 58% identity with Sem-5 of C. elegans, 
66% identity with the D. melanogaster homolog Drk 
and over 99% identity with both rat and mouse 
homologs. 
Mutations 
Note: No known naturally-occurring mutations in 
human GRB2 have been reported. 
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Implicated in 
Normal embryogenesis 
Note: A null mutation introduced into the mouse gene 
for Grb2 was used to demonstrate that Grb2 is required 
during embryogenesis for the differentiation of 
endodermal cells and epiblast formation. Replacing the 
carboxy-terminus of SOS-1 with the Grb2 SH2 domain 
yielded a fusion protein that rescued the defects caused 
by this Grb2 mutation. Grb2 signaling primarily 
regulates differentiation, rather than proliferation, in the 
early mouse embryo. 
Cardiac hypertrophy 
Note: Engineered Grb2+/- mice subjected to cardiac 
stress failed to activate p38 MAP kinase (MAPK14) 
and Jun N-terminal kinase (JNK), and the cardiac 
hypertrophy and fibrosis observed in normal mice were 
blocked. Transgenic mice with dominant-negative 
forms of MAPK p38-alpha and p38-beta developed 
cardiac hypertrophy but were resistant to cardiac 
fibrosis when subjected to cardiac stress. These and 
other findings suggest that Grb2 activity is essential for 
cardiac hypertrophy and fibrosis in response to pressure 
overload, and that different signaling pathways 
downstream of Grb2 regulate fibrosis, fetal gene 
induction, and cardiomyocyte growth. 
Cancer 
Note: As a pivotal activator of cell-cycle control and 
motility pathways downstream of several growth factor 
receptors, GRB2 is involved in oncogenic signaling in 
a wide variety of human tumors. For example, GRB2 
directly interacts with SOS-1 and the Bcr portion of the 
Bcr-Abl fusion protein, a tyrosine kinase oncoprotein 
which has been implicated in the pathogenesis of 
Philadelphia chromosome positive leukemias, such as 
CML, ALL, and AML. GRB2 is rate limiting for 
mammary carcinomas induced by polyomavirus middle 
T antigen. GRB2 over expression has been reported in 
human breast, bladder and prostate cancer cell lines. 
Selective small molecule inhibitors of GRB2 SH2 
domain binding block solid tumor metastasis in animal 
models. 
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